Dataset Information

Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

ABSTRACT: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent.We examined the effects of Bifidobacterium animalis subsp. lactis BB-12® (BB-12®) (3.16 × 109 CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults.In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18-40 years were randomly assigned to: 1) yogurt smoothie with no BB-12® (YS), 2) yogurt smoothie with BB-12® added pre-fermentation (PRE), 3) yogurt smoothie with BB-12® added post-fermentation (POST), 4) BB-12® containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period.Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (??=?211.89?±?75.87 ?g/g, P?=?0.007) and PRE (??=?204.98?±?75.70 ?g/g, P?=?0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2?±?13.2% vs. 24.5?±?13.2%, P?=?0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r?=?-0.22, P?=?0.01), LDL-C (r?=?-0.24, P?=?0.004), age (r?=?-0.33, P < 0.001), and waist circumference (r?=?-0.25, P?=?0.003).BB-12® supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference.This trial was registered at clinicaltrials.gov as NCT01399996 .

SUBMITTER: Lee Y

PROVIDER: S-EPMC5492721 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effects of Bifidobacterium animalis subsp. lactis BB-12<sup>®</sup> on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

Lee Yujin Y Ba Zhaoyong Z Roberts Robert F RF Rogers Connie J CJ Fleming Jennifer A JA Meng Huicui H Furumoto Emily J EJ Kris-Etherton Penny M PM

Nutrition journal 20170629 1

<h4>Background</h4>Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent.<h4>Objective</h4>We examined the effects of Bifidobacterium animalis subsp. lactis BB-12<sup>®</sup> (BB-12<sup>®</sup>) (3.16 × 10<sup>9</sup> CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults.<h4>Methods</h4>In a randomize ...[more]

PMID: 28662676

Similar Datasets

Project description:IntroductionThe consumption of probiotics may influence children's gut microbiome and metabolome, which may reflect shifts in gut microbial diversity composition and metabolism. These potential changes might have a beneficial impact on health. However, there is a lack of evidence investigating the effect of probiotics on the gut microbiome and metabolome of children. We aimed to examine the potential impact of a two (Streptococcus thermophilus and Lactobacillus delbrueckii; S2) vs. three (S2 + Bifidobacterium animalis subsp. lactis strain BB-12) strain-supplemented yogurt.MethodsIncluded in this study were 59 participants, aged one to five years old, recruited to phase I of a double-blinded, randomized controlled trial. Fecal samples were collected at baseline, after the intervention, and at twenty days post-intervention discontinuation, and untargeted metabolomics and shotgun metagenomics were performed.ResultsShotgun metagenomics and metabolomic analyses showed no global changes in either intervention group's gut microbiome alpha or beta diversity indices, except for a lower microbial diversity in the S2 + BB12 group at Day 30. The relative abundance of the two and three intervention bacteria increased in the S2 and S2 + BB12 groups, respectively, from Day 0 to Day 10. In the S2 + BB12 group, the abundance of several fecal metabolites increased at Day 10, including alanine, glycine, lysine, phenylalanine, serine, and valine. These fecal metabolite changes did not occur in the S2 group.DiscussionIn conclusion, there were were no significant differences in the global metagenomic or metabolomic profiles between healthy children receiving two (S2) vs. three (S2 + BB12) probiotic strains for 10 days. Nevertheless, we observed a significant increase (Day 0 to Day 10) in the relative abundance of the two and three probiotics administered in the S2 and S2 + BB12 groups, respectively, indicating the intervention had a measurable impact on the bacteria of interest in the gut microbiome. Future research using longer probiotic intervention durations and in children at risk for gastrointestinal disorders may elucidate if functional metabolite changes confer a protective gastrointestinal effect.

Dataset Information

Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

Publications

Effects of Bifidobacterium animalis subsp. lactis BB-12<sup>®</sup> on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets